Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phas
Summary
Vlad Coric, M.D., Chief Executive Officer of Biohaven, commented, "We are proud to be the first to deliver a positive dataset from two Phase 3 pivotal trials meeting current FDA guidance that shows robust and durable clinical benefit from a single dose of an oral CGRP receptor antagonist in the acute treatment of migraine.Richard B. Lipton, M.D., Vice Chair of Neurology, Professor of Epidemiology and Population Health and Director of the Montefiore Headache Center, at the Albert Einstein College of Medicine, and Chair of Biohavens CGRP Scientific Advisory Board added, "The single dose data from these two clinical trials are very exciting as rimegepant brings forward a novel mechanism of action that has demonstrated important clinical benefit to patients.For full presentation including use of rescue medications, patient preference, safety summary and other secondary outcome measures see the Events page on the company website (see link below).Biohaven hosted a conference call and webcast on April 22, 2018 concurrent with the American Academy of Neurology meeting in Los Angeles to discuss the secondary outcome measures available from these two Phase 3 clinical trials.Related Links LOS ANGELES, April 22, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) today announced the results of key secondary outcome measures from Phase 3 clinical trials (BHV3000-301 and BHV3000-302) of rimegepant, the first oral CGRP receptor antagonist to deliver positive data on pain freedom and most bothersome symptom in two pivotal Phase 3 trials in acute treatment of migraine.